lunes, 29 de octubre de 2018

Cystic Fibrosis News Today Weekly Digest


Cystic Fibrosis Weekly Update

Contents:

#NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach

Oct 29, 2018 07:30 am | Larry Luxner



NORD Summit 2018With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or Republicans stay in control, no matter […]
The post #NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike #NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach on Facebook

#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Phase 2 Study Shows

Oct 29, 2018 07:00 am | Ana Pena



acebilustatOnce-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency and delays the onset of pulmonary exacerbations in CF patients, results from a Phase 2 study show. Patients with better lung function benefited most, with a 96% higher chance of being free of exacerbations after 48 weeks of […]
The post #NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Phase 2 Study Shows appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike #NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Phase 2 Study Shows on Facebook
 

Recent News

#NACFC2018 – Preclinical Study Data Demonstrate Lenabasum’s Potential to Prevent Inflammatory Signals in CF
#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators
PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show
Santhera’s Potential CF Inhalation Therapy Favored for Orphan Drug Status in EU
Compliance Is One of Our Toughest Mental and Physical Battles

No hay comentarios:

Publicar un comentario